To further expand trading opportunities and enhance your Futures trading experience, MEXC will launch FIG, IONS, FRMI and BOT USDT-M Stock Futures on the Futures market. These new listings offer a flexible and efficient way to gain exposure to some of the most prominent equities. Futures trading will be available immediately upon listing, with Futures Grid Bot strategies available within 5 minutes of listing.
Futures Trading Details
Feature | Details | Details | Details | Details |
Trading Pair | FIGUSDT | IONSUSDT | FRMIUSDT | BOTUSDT |
Listing Time | Jul 13, 2026, 10:50 (UTC) | Jul 13, 2026, 10:50 (UTC) | Jul 13, 2026, 10:50 (UTC) | Jul 13, 2026, 10:50 (UTC) |
Max Leverage | 20x | 20x | 20x | 20x |
Margin Mode | Cross & Isolated | Cross & Isolated | Cross & Isolated | Cross & Isolated |
Trading Hours | 24/7 | 24/7 | 24/7 | 24/7 |
Introduction
FIG: Figma, Inc. develops a browser-based tool for designing user interfaces that helps design and development teams build various products. The company offers Figma Design, a collaborative design tool for teams that explore ideas and gather feedback, build realistic prototypes, and streamline product development with design systems; Dev Mode to inspect designs and translate them into code without changing the design file; FigJam to define ideas, align on decisions, and move work forward & all in one place; and Figma Slides, a presentation tool built for designers and their teams.
IONS: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
FRMI: Fermi Inc building a private power campus for AI-centric customers, developing and leasing large-scale, grid-independent energy generation and high-performance computing facilities purpose-built for the hyperscale era. The company is also developing a private energy and site infrastructure platform across the campus to support multiple powered shell buildings and a diversified, integrated power supply, including private power generation and delivery infrastructure, substations, internal distribution networks, water and cooling systems, and other essential infrastructure. In addition to powered shell facilities, it may offer long-term ground leases to tenants that elect to construct their own powered shell facilities on land, with or without integrated power delivery.
BOT: BOT tracks the value of 1 share of common stock in RoboStrategy, Inc. RoboStrategy is a publicly listed closed-end investment company focused on robotics and embodied artificial intelligence, investing in equity and equity-linked securities of private and public companies across robotics, humanoid systems, and physical AI.
